Ret proto-oncogene receptor and Glial cell line-derived neurotrophic factor family receptor alpha-1 (RET and GFRα1)

RET and GFRα1 refer to a high-affinity ligand-receptor system crucial for neurotrophic signaling and organ development. RET (Ret proto-oncogene receptor) is a single-pass transmembrane receptor tyrosine kinase, while GFRα1 (Glial cell line-derived neurotrophic factor family receptor alpha-1) is a glycosylphosphatidylinositol (GPI)-anchored co-receptor. The canonical ligand is GDNF (Glial cell line-derived neurotrophic factor). Ligand (GDNF) binding first occurs to GFRα1, which then presents the ligand to RET, facilitating RET dimerization and autophosphorylation and triggering downstream signaling pathways including RAS/MAPK, PI3K/AKT, and PLCγ. The RET/GFRα1 receptor complex is essential for embryonic development of the nervous system, kidneys, and other organs, and it plays a critical role in adult neuroprotection as well as certain forms of cell adhesion[4][5][7]. Aberrant RET signaling, often through mutation, amplification, or gene fusion, drives oncogenesis in numerous human cancers, and RET is a clinically validated target in oncology[8]. Both RET and GFRα1 are required for signaling, but GFRα1 can also exist in a soluble form, mediating trans and paracrine activation of RET[2][6]. Drugs targeting this receptor system include selective RET kinase inhibitors, which have shown clinical efficacy in RET-driven cancers but can encounter resistance mutations and class-specific toxicities[8].

Other names

RET proto-oncogeneRET receptor tyrosine kinaseGFR alpha-1GDNF family receptor alpha-1GFRα1GDNF receptor alpha-1Ret receptorGlia-derived neurotrophic factor receptor alpha-1

Inhibition of RET tyrosine kinase activity, thus blocking downstream survival and proliferation pathways Prevention of RET autophosphorylation and disrupts signaling complex formation